Profit structures of list drug companies remarkably improved.

The listed drug companies having a fiscal year ended at March 31, reported the business performance of the 1st quarter of FY2005, showing a substantial improvement of their profits largely due to the aggressive marketing activities for their major and new products at 8.44% of sales up and 9.93% of net income growth compared to the same period of the previous year (13% sales up but the net incom...